Spectrum Pharmaceuticals (SPPI) +4.3%, with the main news being that the biotech has started a...

|About: Spectrum Pharmaceuticals,... (SPPI)|By:, SA News Editor

Spectrum Pharmaceuticals (SPPI) +4.3%, with the main news being that the biotech has started a Phase 1 trial evaluating the safety and tolerability of its RenaZorb drug in healthy volunteers. RenaZorb is a potential treatment of hyperphosphatemia (high phosphate levels in the blood) in patients with chronic kidney disease. (PR)